Fetal vs Perinatal EVs as potential OA Therapeutics
Fetal vs Perinatal EVs as potential OA Therapeutics September 2nd, 2025, Vienna, Austria We are pleased to share a new publication
By Giulia Corso|2025-09-02T08:43:58+00:00September 2nd, 2025|collaboration, EV cell factories, mesenchymal stromal cells, publication, recent highlights EV, telomerized cells|
Fetal vs Perinatal EVs as potential OA Therapeutics September 2nd, 2025, Vienna, Austria We are pleased to share a new publication
By admin|2024-08-30T09:08:35+00:00April 9th, 2021|recent highlights EV|
Analysis of miRNA cargo of extracellular vesicles from Wharton´s Jelly derived mesenchymal stem cells WJ-MSC/TERT273 application: characterization and quality control for stable production of extracellular
By admin|2021-04-08T10:29:39+00:00April 8th, 2021|Recent highlights substance testing|
Study of myofibroblast differentiation monitoring the effect of exogenous factors on myofibroblast differentiation in a model using TGFß as inducer of alpha smooth muscle actin in fibroblasts
By admin|2021-04-09T09:08:06+00:00April 8th, 2021|recent highlights EV|
Scratch assay for monitoring skin cell proliferation/migration screening for substances that induce fibroblast growth application: identification of agents with potential to target impaired wound healing